MARKET

ATRC

ATRC

Atricure
NASDAQ
45.56
-0.40
-0.87%
After Hours: 45.56 0 0.00% 16:01 12/02 EST
OPEN
45.09
PREV CLOSE
45.96
HIGH
46.02
LOW
43.80
VOLUME
132.68K
TURNOVER
0
52 WEEK HIGH
74.85
52 WEEK LOW
32.51
MARKET CAP
2.12B
P/E (TTM)
-37.0648
1D
5D
1M
3M
1Y
5Y
AtriCure to Present at 34th Annual Piper Sandler Healthcare Conference
MASON, Ohio, November 08, 2022--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will pres...
Business Wire · 11/08 13:00
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $65
Benzinga · 11/02 14:14
--Canaccord Genuity Adjusts AtriCure Price Target to $65 From $72, Maintains Buy Rating
--Canaccord Genuity Adjusts AtriCure Price Target to $65 From $72, Maintains Buy Rating
MT Newswires · 11/02 12:48
--Needham Adjusts Price Target on AtriCure to $55 From $65, Maintains Buy Rating
--Needham Adjusts Price Target on AtriCure to $55 From $65, Maintains Buy Rating
MT Newswires · 11/02 12:32
Needham Maintains Buy on AtriCure, Lowers Price Target to $55
Benzinga · 11/02 10:02
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -8% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/01 21:55
AtriCure Q3 EPS $(0.27) Misses $(0.25) Estimate, Sales $83.20M Beat $81.33M Estimate
Benzinga · 11/01 20:50
AtriCure GAAP EPS of -$0.27 misses by $0.02, revenue of $83.2M beats by $1.88M
Seekingalpha · 11/01 20:04
More
About ATRC
AtriCure, Inc. provides technologies for the treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain. It develops, manufactures, and sells devices for the surgical ablation of cardiac tissue, systems designed for the exclusion of the left atrial appendage and devices designed to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to medical centers. Its ablation and left atrial appendage management (LAAM) products are used by physicians during both open-heart and minimally invasive procedures. Its products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its products for appendage management include AtriClip System and LARIAT System.

Webull offers kinds of AtriCure Inc. stock information, including NASDAQ:ATRC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRC stock methods without spending real money on the virtual paper trading platform.